<DOC>
	<DOCNO>NCT02783196</DOCNO>
	<brief_summary>This study undertaken search whether glucagon-like peptide-1 ( GLP-1 ) analogue , Liraglutide , enhance clock gene AMPK-SIRT-1 mRNA expression , may reverse metabolic abnormality type 2 diabetes , improve overall glycemic excursion , inflammatory cytokine β-cell function type 2 diabetes individual . The investigator aim compare effect 40 day treatment Liraglutide ( LIR ) vs. 40 day placebo ( PLA ) T2D participant follow end point : Primary end-points : - Change oscillation CG ( i.e . CLOCK , BMAL1 , Per1 , Per2 , Cry1 , Cry2 , Rev-erb-alpha Ror-alpha ) , AMPK , SIRT1 inflammatory cytokine mRNA expression white blood cell ( WBCs ) . Secondary end-points : - Overall daily glycemic variation assess continuous glucose monitoring system ( CBMS ) - Serum level inflammatory cytokine ( TNF-α , IL-1β , IL-6 ) - β-Cell function derive glucose insulin response OGTT</brief_summary>
	<brief_title>Effect Liraglutide Clock Genes</brief_title>
	<detailed_description>Background : Cumulative evidence strongly implicate disruption clock gene ( CGs ) play causative role insulin resistance , hyperglycemia β-cell dysfunction type 2 diabetes ( T2D ) . CGs synchronize meal timing . Indeed , animal patient T2D , restrict feed specific hour , large meal assign breakfast reduce dinner , reset restore CG expression , result improved glycemic control , insulin sensitivity reduction HbA1c compare isocaloric diet different meal timing ( small breakfast overeat dinner ) . Since glucagon-like peptide-1 ( GLP-1 ) secrete within minute response food ingestion influence multiple humoral neural signal pathway may influence CG expression many cell , suggest GLP-1 may reset signal CGs , synchronize food entrainment CGs expression thereby influence glucose metabolism . In fact , several study animal model , document GLP-1 analog either exenatide liraglutide , via activation CG expression AMPK-SIRT-1 pathway , improve insulin sensitivity , muscular glucose uptake , reduce hepatic cardiac steatosis , inflammatory cytokine oxidative stress , enhance β-cell insulin secretion proliferation , independently GLP-1 analog glucose-lowering effect . To best investigator knowledge , systemic study human date investigate change expression CGs AMPK-SIRT-1 pathway , concomitantly effect glycemic control , insulin sensitivity , beta cell function , inflammatory cytokine T2D individual treatment Liraglutide GLP-1 analog . Hypothesis : The investigator hypothesize , Liraglutide , enhance CG AMPK-SIRT-1 expression may reverse metabolic abnormality T2D , improve insulin sensitivity , overall glycemic excursion , inflammatory cytokine β-cell function T2D individual . Objectives : The investigator aim compare effect 40 day treatment Liraglutide ( LIR ) vs. 40 day placebo ( PLA ) T2D participant follow end point : Primary end-points : - Change oscillation CG ( i.e . CLOCK , BMAL1 , Per1 , Per2 , Cry1 , Cry2 , Rev-erb-alpha , Ror-alpha ) , AMPK , SIRT1 inflammatory cytokine mRNA expression white blood cell ( WBCs ) . Secondary end-points : - Overall daily glycemic variation assess continuous glucose monitoring system ( CBMS ) - Serum level inflammatory cytokine ( TNF-α , IL-1β , IL-6 ) - β-Cell function derive glucose insulin response OGTT Methods : In randomize , double blind crossover-within-subject clinical trial , investigator study 18 weight- match obese overweight participant know T2D , diagnose &lt; 20 year , HbA1c 7.0 10 % , BMI : 26-32 kg/m2 treat diet alone diet plus metformin , sodium/glucose cotransporter 2 ( SGLT2 ) inhibitor ( gliflozins ) . All 18 T2D participant undergo randomization baseline two 40 day treatment period , either start LIR treatment , 2 week wash-out , crossover second treatment period 40 day PLA , vice-versa , start first period PLA 40 day crossover 40 day LIR . The treatment LIR PLA up-titrated progressively 0.1ml 0.3ml avoid secondary effect LIR . Expected result : The investigator expect LIR lead enhance expression diurnal oscillation CGs AMPK , SIRT1 pathway , reduce serum inflammatory cytokine , overall daily glycemic variation improve insulin sensitivity β-Cell function . Significance study : Showing GLP-1 analog Liraglutide , improve β-cell function type 2 diabetic individual , enhance clock gene mRNA expression AMPK-SRIT1 pathway , may change approach Liraglutide treatment , excellent anti-diabetic agent beneficial effect diabetic heart , drug ability synchronize body metabolism improve glucose homeostasis health disease . Presently , many available drug treatment type 2 diabetes , mode action make advantageous . If GLP-1 analog reduces glucose , body weight cardiovascular risk , also synchronize circadian clock , would make Liraglutide drug choice ( immediately metformin ) treatment obesity , early diabetes prevention T2D complication cardiovascular event high risk patient , moreover , Liraglutide influence clock gene expression , may prevent several age relate disorder link disruption clock gene .</detailed_description>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Inclusion Criteria 1 . Patients T2D diagnose diagnosed &lt; 20 year . 2 . HbA1c : 7 10 % screen qualification 3 . BMI : 2632 kg/m2 . 4 . Men woman 5 . Between age 30 75 year . 6 . Patients treat diet alone diet plus metformin SGLT2 inhibitor , stable dose least 3 month . 7 . Concomitant medication i.e . antihypertensive , antilipidemic , antithrombotic drug allow . 8 . Patients usually wake 06:00 07:00 go sleep 22:00 24:00 . 9 . Subjects shift work within 6 month study cross time zone within 1 month study . 10 . For woman child bear potential , negative pregnancy test willingness use birth control study : 1 . Type 1 diabetes secondary form diabetes . 2 . Use glucoselowering therapy apart metformin SGLT2 inhibitor . 3 . Treatment GLP1 receptor agonist , dipeptidyl peptidase4 ( DPP4 ) inhibitor within last 3 month . 4 . Major illness life expectancy &lt; 5 year . 5 . Serum creatinine level &gt; 2mg/d renal dysfunction : ( estimate glomerular filtration rate &lt; 45 mL/min/1.73 m2 ) . 6 . Hepatic dysfunction : liver disease transaminase level &gt; 3fold normal . 7 . History acute chronic pancreatitis high risk pancreatitis i.e . triglycerides 400 mg/dl alcoholism . 8 . Family personal history Multiple Endocrine Neoplasia type 2 ( MEN2 ) familial medullary thyroid carcinoma . 9 . Familial personal history multiple endocrine neoplasia type 2 ( MEN2 ) , familial nonfamilial medullary thyroid carcinoma ( MTC ) 10 . Malignant neoplasm require chemotherapy , surgery , radiation palliative therapy within previous 5 year ( exception basal cell skin cancer ) . 11 . Those take psychotropic , anorectic medication , steroid treatment illicit drug abuse alcoholism within one year prior study onset . 12 . Congestive heart failure cardiac arrhythmia i.e . atrial fibrillation . 13 . Pregnancy lactation . 14 . Eating disorder subject bariatric surgery affect gastroparesis . 15 . Night rotate shift worker cross 2 time zone 2week period prior study onset . 16 . No change medication nutrition supplement physical activity make study period . 17 . Known proliferative retinopathy maculopathy</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>